Vol. 7, Issue 1, Part B (2025)

Insomnia, a prevalent sleep disorder affecting approximately 30% of adults globally, is characterized by persistent difficulties in sleep initiation, maintenance, or non-restorative sleep, leading to significant daytime impairment. Traditional treatments, including pharmacotherapy and cognitive-behavioral interventions, face limitations such as side effects, dependency risks, and variable patient compliance. This review explores pulsed electromagnetic field (PEMF) therapy as a novel, non-invasive alternative for insomnia management. 
PEMF therapy employs low-frequency electromagnetic pulses (1-4 Hz) to modulate brain activity, enhance delta wave synchronization, and promote neuroplasticity. By stimulating melatonin production, reducing cortisol levels, and balancing autonomic nervous system activity (e.g., increasing parasympathetic tone), PEMF addresses hyperarousal-a key pathophysiological feature of insomnia. Clinical studies, including double-blind trials, demonstrate its efficacy in improving sleep latency, duration, and quality, with effects attributed to mechanisms such as GABAergic modulation, serotonin regulation, and mitochondrial function enhancement. Optimal parameters include intensities of 5-50 µT, applied for 20-60 minutes before bedtime, targeting the head or upper body to entrain sleep-associated brainwaves. 
Notably, PEMF’s dual role in alleviating comorbid pain and inflammation further supports its therapeutic potential, offering a holistic approach without the side effects of conventional sleep aids. Systematic reviews underscore its safety profile, though contraindications exist for individuals with implanted electronic devices. While preliminary evidence is promising, further rigorous, large-scale trials are needed to standardize protocols and confirm long-term benefits. PEMF therapy emerges as a compelling adjunct or alternative for insomnia, bridging gaps in current treatment paradigms through its multimodal action on neural, hormonal, and cellular pathways.